Epistatic interactions promote resistance against direct-acting antivirals targeting the HCV NS3 protein
Preprint
- 27 January 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Direct-acting antiviral agents (DAAs) provide efficacious therapeutic treatments for chronic Hepatitis C virus (HCV) infection. However, emergence of drug resistance mutations (DRMs) can greatly affect treatment outcomes and impede virological cure. While multiple DRMs have been observed for all currently used DAAs, the evolutionary determinants of such mutations are not currently well understood. Here, by considering DAAs targeting the nonstructural 3 (NS3) protein of HCV, we present results suggesting that epistasis plays an important role in the evolution of DRMs. Using a sequence-based fitness landscape model that we validate using experimental data, we identify specific DRMs that are associated with strong epistatic interactions, and these are found to be enriched in multiple NS3-specific DAAs. We further demonstrate, using evolutionary modelling, that the identified DRMs involve compensatory mutational interactions that facilitate relatively easy escape from drug-induced selection pressures. Our results indicate that accounting for epistasis is important for designing future HCV NS3-targeting DAAs.Keywords
All Related Versions
- Version 1, 2023-01-27, Research Square
- Published version: Nature Communications, 14 (1), 1.
This publication has 64 references indexed in Scilit:
- Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1aiScience, 2021
- Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instabilityJournal of Biological Chemistry, 2021
- Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018Drug Resistance Updates, 2018
- Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized studyHepatology, 2016
- Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJournal of Hepatology, 2015
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR studyHepatology, 2013
- Translating HIV Sequences into Quantitative Fitness Landscapes Predicts Viral Vulnerabilities for Rational Immunogen DesignImmunity, 2013
- Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II studyHepatology, 2012
- Accessory Mutations Maintain Stability in Drug-Resistant HIV-1 ProteaseJournal of Molecular Biology, 2011